{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:29:59Z","timestamp":1776162599210,"version":"3.50.1"},"reference-count":61,"publisher":"Cambridge University Press (CUP)","issue":"S1","license":[{"start":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T00:00:00Z","timestamp":1483401600000},"content-version":"unspecified","delay-in-days":33,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:p>There are several new and emerging medication interventions for both the acute and maintenance treatment phases of schizophrenia. Recently approved are 2 new dopamine receptor partial agonists, brexpiprazole and cariprazine, as well as 2 new long-acting injectable antipsychotic formulations, aripiprazole lauroxil and 3-month paliperidone palmitate. Although differences in efficacy compared to other available choices are not expected, the new oral options offer different tolerability profiles that may be attractive for individual patients who have had difficulties with older medications. The new long-acting injectable options provide additional flexibility in terms of increasing the time interval between injections. In Phase III of clinical development is a novel antipsychotic, lumateperone (ITI-007), that appears to have little in the way of significant adverse effects. Deutetrabenazine and valbenazine are agents in Phase III for the treatment of tardive dyskinesia, a condition that can be found among persons receiving chronic antipsychotic therapy. On the horizon are additional injectable formulations of familiar antipsychotics, aripiprazole and risperidone, that may be more convenient than what is presently available.<\/jats:p>","DOI":"10.1017\/s1092852916000729","type":"journal-article","created":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T12:34:11Z","timestamp":1483446851000},"page":"1-12","source":"Crossref","is-referenced-by-count":15,"title":["Emerging pharmacological therapies in schizophrenia: what\u2019s new, what\u2019s different, what\u2019s next?"],"prefix":"10.1017","volume":"21","author":[{"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2017,1,3]]},"reference":[{"key":"S1092852916000729_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.01.038"},{"key":"S1092852916000729_ref3","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S91917"},{"key":"S1092852916000729_ref23","unstructured":"Janssen. INVEGA TRINZA (paliperidone palmitate) extended-release injectable suspension, for intramuscular use. Prescribing information. Revised March 2016. Available at: https:\/\/www.janssenmd.com\/pdf\/invega-trinza\/INVEGA-TRINZA_PI.pdf. Last accessed September 27, 2016."},{"key":"S1092852916000729_ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.03.020"},{"key":"S1092852916000729_ref49","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1029573"},{"key":"S1092852916000729_ref48","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P312"},{"key":"S1092852916000729_ref40","unstructured":"O\u2019Gorman C , Vanover KE , Davis RE , et al. ITI-007 for the treatment of schizophrenia: safety & tolerability data to date from two double-blind, randomized, placebo-controlled clinical trials. Poster presentation P6-147. Presented at: American Psychiatric Association Annual Meeting; May 14\u201318, 2016; Atlanta, GA."},{"key":"S1092852916000729_ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0132-7"},{"key":"S1092852916000729_ref44","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.07m03890yel"},{"key":"S1092852916000729_ref36","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.597"},{"key":"S1092852916000729_ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.06.030"},{"key":"S1092852916000729_ref8","doi-asserted-by":"publisher","DOI":"10.3371\/CSRP.MCCI.010316"},{"key":"S1092852916000729_ref60","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000479"},{"key":"S1092852916000729_ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2015.08.026"},{"key":"S1092852916000729_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.04.013"},{"key":"S1092852916000729_ref4","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13049su1c.04"},{"key":"S1092852916000729_ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-012-2896-5"},{"key":"S1092852916000729_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"S1092852916000729_ref35","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.917089"},{"key":"S1092852916000729_ref51","unstructured":"Auspex Pharmaceuticals. Treating Hyperkinetic Movement Disorders. December 2014. Available at: http:\/\/files.shareholder.com\/downloads\/AMDA-2IEHYZ\/0x0x797219\/01a86e01-44d4-4ee0-9fb2-69537c486954\/Piper%20Jaffray%20Presentation%2012-2-14.pdf. Last accessed September 27, 2016."},{"key":"S1092852916000729_ref12","article-title":"Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomised, double-blind, placebo-controlled study","author":"Fleischhacker","year":"In","journal-title":"Int J Neuropsychopharmacol"},{"key":"S1092852916000729_ref56","unstructured":"Alkermes. Alkermes submits supplemental new drug application to FDA for two-month dosing option of ARISTADA\u00ae for treatment of schizophrenia. Press release. August 8, 2016. Available at: http:\/\/investor.alkermes.com\/mobile.view?c=92211&v=203&d=1&id=2193630. Last accessed September 27, 2016."},{"key":"S1092852916000729_ref55","unstructured":"Marder S , Knesevich MA , Hauser RA , Liang GS , O\u2019Brien CF . KINECT 3: a randomized, double-blind, placebo-controlled Phase 3 trial of valbenazine (NBI-98854) for tardive dyskinesia. Poster presentation P8-082. Presented at: American Psychiatric Association Annual Meeting; May 14\u201318, 2016; Atlanta, GA."},{"key":"S1092852916000729_ref57","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.141"},{"key":"S1092852916000729_ref2","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903061309"},{"key":"S1092852916000729_ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.0241"},{"key":"S1092852916000729_ref43","unstructured":"Intra-Cellular Therapies. Corporate Presentation, 2016. Available at: http:\/\/files.shareholder.com\/downloads\/AMDA-2O83FW\/2571108091x0x862131\/DF51C35D-C947-4959-B5A6-DC4B9BC3CF76\/ITCI_Corporate_Presentation.pdf. Last accessed September 27, 2016."},{"key":"S1092852916000729_ref53","unstructured":"Anderson KE , Factor SA , Hauser RA , et al. A randomized, double-blind, placebo-controlled trial of deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD). Poster presentation P8-004. Presented at: American Psychiatric Association Annual Meeting; May 14\u201318, 2016; Atlanta, GA."},{"key":"S1092852916000729_ref16","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m09997"},{"key":"S1092852916000729_ref31","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m07530"},{"key":"S1092852916000729_ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.11.041"},{"key":"S1092852916000729_ref5","doi-asserted-by":"publisher","DOI":"10.1017\/S109285291500070X"},{"key":"S1092852916000729_ref46","doi-asserted-by":"publisher","DOI":"10.1177\/070674370505000907"},{"key":"S1092852916000729_ref32","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.113.134213"},{"key":"S1092852916000729_ref50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial","volume":"316","author":"Frank","year":"2016","journal-title":"JAMA"},{"key":"S1092852916000729_ref29","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S45401"},{"key":"S1092852916000729_ref54","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26330"},{"key":"S1092852916000729_ref37","unstructured":"Janssen. INVEGA SUSTENNA (paliperidone palmitate) extended-release injectable suspension, for intramuscular use. Prescribing information. Revised March 2016. Available at: https:\/\/www.invegasustennahcp.com\/sites\/www.invegasustennahcp.com\/files\/prescribing-information-invegasustenna.pdf. Last accessed September 27, 2016."},{"key":"S1092852916000729_ref21","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2016.1121809"},{"key":"S1092852916000729_ref27","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.160432"},{"key":"S1092852916000729_ref47","doi-asserted-by":"publisher","DOI":"10.1177\/070674370505001110"},{"key":"S1092852916000729_ref30","unstructured":"Otsuka. ABILIFY MAINTENA\u00ae (aripiprazole) for extended-release injectable suspension, for intramuscular use. Prescribing information. Revised August 2016. Available at: https:\/\/www.otsuka-us.com\/media\/static\/Abilify-M-PI.pdf. Last accessed September 27, 2016."},{"key":"S1092852916000729_ref42","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2016.1174577"},{"key":"S1092852916000729_ref6","unstructured":"Otsuka. REXULTI (brexpiprazole) tablets, for oral use. Prescribing information. Revised September 2016. Available at: https:\/\/www.otsuka-us.com\/media\/static\/Rexulti-PI.pdf. Last accessed September 27, 2016."},{"key":"S1092852916000729_ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.07.007"},{"key":"S1092852916000729_ref17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and Safety of cariprazine in acute exacerbation of schizophrenia: results from an international, Phase III clinical trial","volume":"35","author":"Kane","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"S1092852916000729_ref20","unstructured":"Alkermes. ARISTADA (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular use. Prescribing information. Revised October 2015. Available at: http:\/\/www.alkermes.com\/assets\/content\/files\/AristadaPI.pdf. Last accessed September 27, 2016."},{"key":"S1092852916000729_ref9","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2015.1086269"},{"key":"S1092852916000729_ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2014.12.013"},{"key":"S1092852916000729_ref15","doi-asserted-by":"publisher","DOI":"10.3371\/1935-1232-10.2.109"},{"key":"S1092852916000729_ref22","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09741"},{"key":"S1092852916000729_ref26","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12752"},{"key":"S1092852916000729_ref10","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.14101275"},{"key":"S1092852916000729_ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3704-1"},{"key":"S1092852916000729_ref52","doi-asserted-by":"publisher","DOI":"10.1002\/jlcr.3031"},{"key":"S1092852916000729_ref59","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.366"},{"key":"S1092852916000729_ref45","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.8.1316"},{"key":"S1092852916000729_ref7","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12714"},{"key":"S1092852916000729_ref14","unstructured":"Actavis. VRAYLAR (cariprazine) capsules, for oral use. Prescribing Information. Revised September 2015. Available at: http:\/\/www.allergan.com\/assets\/pdf\/vraylar_pi. Last accessed September 27, 2016."},{"key":"S1092852916000729_ref25","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw018"},{"key":"S1092852916000729_ref39","unstructured":"Davis RE , Vanover KE , O\u2019Gorman C , et al. ITI-007 for the treatment of schizophrenia: primary & secondary efficacy endpoints and subgroup analyses from two positive randomized, double-blind, placebo-controlled clinical trials. Poster presentation P6-146. Presented at: American Psychiatric Association Annual Meeting; May 14\u201318, 2016; Atlanta, GA."}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852916000729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T13:35:26Z","timestamp":1658324126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852916000729\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":61,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S1092852916000729"],"URL":"https:\/\/doi.org\/10.1017\/s1092852916000729","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}